FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281996145> ?p ?o ?g. }

• W4281996145 endingPage "2047" @default.
• W4281996145 startingPage "2047" @default.
• W4281996145 abstract "2047 Background: Paxalisib, a potent oral selective brain-penetrant small molecule PI3K/mTOR inhibitor, has shown activity in nonclinical brain cancer models and promising phase 1 data in progressive / recurrent high-grade gliomas (NCT01547546). This multicenter phase 2 progressive design trial (NCT03522298) aimed to establish the maximum tolerated dose (MTD) for once-daily (QD) dosing, and to evaluate safety, tolerability, pharmacokinetics (PK), and clinical activity of paxalisib in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status. Methods: Eligible patients were males or females, aged ≥18 years, who had undergone surgical resection and chemoradiotherapy (Stupp Regimen), and were considered to be progression free before starting adjuvant paxalisib. Stage 1 used a standard 3+3 dose-escalation design to determine the MTD in this population. Stage 2 was a two-arm, open-label, expansion cohort with patients randomized 1:1 to receive paxalisib at the MTD under fed or fasted conditions. In both stages, treatment comprised daily paxalisib administered in 28-day cycles, continuously until disease progression or unacceptable toxicity. Efficacy analyses are based on investigator review and from date of diagnosis. Results: Patients (n = 30; 70.0% males, 83.3% white, mean age 58.5 years) had a mean time since diagnosis of 3.75 months. The majority (n = 29) received between 1 and 6 treatment cycles and one received 29 cycles. In Stage 1 (n = 9), an MTD of 60mg was established on the dose-limiting toxicities of hyperglycemia (n = 1) and stomatitis (n = 1) at 75mg. Paxalisib at 60mg was well-tolerated and adverse events were consistent with other PI3K inhibitor medicines. At the MTD (60mg), the PK profile was linear and dose-proportional with no differences in T max and elimination half-life under fed and fasted conditions. For the overall ITT population, the median progression free survival was 8.4 months (RANO) and 8.6 months (mRANO) and the median overall survival was 15.7 months. In a mITT (n = 22 patients treated with 60mg daily and ≥1 post-baseline assessment), the median PFS was 9.6 months (mRANO). Conclusions: The primary study endpoints were met; PK and safety were consistent with prior clinical experience. The MTD showed encouraging clinical activity, prolonging PFS and improving OS. Further efficacy confirmation of paxalisib 60 mg QD in newly diagnosed glioblastoma in a pivotal trial is ongoing (GBM AGILE, NCT03970447). Clinical trial information: NCT03522298." @default.
• W4281996145 created "2022-06-13" @default.
• W4281996145 creator A5006374240 @default.
• W4281996145 creator A5013663538 @default.
• W4281996145 creator A5021656597 @default.
• W4281996145 creator A5027114750 @default.
• W4281996145 creator A5029581528 @default.
• W4281996145 creator A5036347055 @default.
• W4281996145 creator A5056817906 @default.
• W4281996145 creator A5062059537 @default.
• W4281996145 creator A5063511816 @default.
• W4281996145 creator A5071814678 @default.
• W4281996145 date "2022-06-01" @default.
• W4281996145 modified "2023-10-16" @default.
• W4281996145 title "Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results." @default.
• W4281996145 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.2047" @default.
• W4281996145 hasPublicationYear "2022" @default.
• W4281996145 type Work @default.
• W4281996145 citedByCount "4" @default.
• W4281996145 countsByYear W42819961452022 @default.
• W4281996145 countsByYear W42819961452023 @default.
• W4281996145 crossrefType "journal-article" @default.
• W4281996145 hasAuthorship W4281996145A5006374240 @default.
• W4281996145 hasAuthorship W4281996145A5013663538 @default.
• W4281996145 hasAuthorship W4281996145A5021656597 @default.
• W4281996145 hasAuthorship W4281996145A5027114750 @default.
• W4281996145 hasAuthorship W4281996145A5029581528 @default.
• W4281996145 hasAuthorship W4281996145A5036347055 @default.
• W4281996145 hasAuthorship W4281996145A5056817906 @default.
• W4281996145 hasAuthorship W4281996145A5062059537 @default.
• W4281996145 hasAuthorship W4281996145A5063511816 @default.
• W4281996145 hasAuthorship W4281996145A5071814678 @default.
• W4281996145 hasConcept C126322002 @default.
• W4281996145 hasConcept C141071460 @default.
• W4281996145 hasConcept C143998085 @default.
• W4281996145 hasConcept C197934379 @default.
• W4281996145 hasConcept C203092338 @default.
• W4281996145 hasConcept C2777288759 @default.
• W4281996145 hasConcept C2778375690 @default.
• W4281996145 hasConcept C2781413609 @default.
• W4281996145 hasConcept C2908647359 @default.
• W4281996145 hasConcept C31760486 @default.
• W4281996145 hasConcept C535046627 @default.
• W4281996145 hasConcept C71924100 @default.
• W4281996145 hasConcept C99454951 @default.
• W4281996145 hasConceptScore W4281996145C126322002 @default.
• W4281996145 hasConceptScore W4281996145C141071460 @default.
• W4281996145 hasConceptScore W4281996145C143998085 @default.
• W4281996145 hasConceptScore W4281996145C197934379 @default.
• W4281996145 hasConceptScore W4281996145C203092338 @default.
• W4281996145 hasConceptScore W4281996145C2777288759 @default.
• W4281996145 hasConceptScore W4281996145C2778375690 @default.
• W4281996145 hasConceptScore W4281996145C2781413609 @default.
• W4281996145 hasConceptScore W4281996145C2908647359 @default.
• W4281996145 hasConceptScore W4281996145C31760486 @default.
• W4281996145 hasConceptScore W4281996145C535046627 @default.
• W4281996145 hasConceptScore W4281996145C71924100 @default.
• W4281996145 hasConceptScore W4281996145C99454951 @default.
• W4281996145 hasIssue "16_suppl" @default.
• W4281996145 hasLocation W42819961451 @default.
• W4281996145 hasOpenAccess W4281996145 @default.
• W4281996145 hasPrimaryLocation W42819961451 @default.
• W4281996145 hasRelatedWork W2009096079 @default.
• W4281996145 hasRelatedWork W2114699723 @default.
• W4281996145 hasRelatedWork W2995532498 @default.
• W4281996145 hasRelatedWork W3125059937 @default.
• W4281996145 hasRelatedWork W3166594929 @default.
• W4281996145 hasRelatedWork W3201319284 @default.
• W4281996145 hasRelatedWork W4229452767 @default.
• W4281996145 hasRelatedWork W4284988128 @default.
• W4281996145 hasRelatedWork W4311628015 @default.
• W4281996145 hasRelatedWork W4312139687 @default.
• W4281996145 hasVolume "40" @default.
• W4281996145 isParatext "false" @default.
• W4281996145 isRetracted "false" @default.
• W4281996145 workType "article" @default.